Trial · NCT01404208
2/2 D-Cycloserine Augmentation of CBT for Pediatric OCD
NCT01404208, Not applicable, Completed, Massachusetts General Hospital; results first posted 2017-02-27
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. 2/2 D-Cycloserine Augmentation of CBT for Pediatric OCD. Trials, record NCT01404208. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01404208
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- 2/2 D-Cycloserine Augmentation of CBT for Pediatric OCD
- NCT number
- NCT01404208
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 206 participants, actual
- Lead sponsor
- Massachusetts General Hospital
- Conditions
- Obsessive-Compulsive Disorder
- Interventions
- D-Cycloserine, Placebo
- First posted
- 2011-07-27
- Last updated
- 2017-03-28
- Results first posted
- 2017-02-27
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) | Change from Score at Randomization to Post Treatment | The CY-BOCS is a measure of severity of OCD symptoms, including interference, time spent on thoughts or behaviors, distress, resistance, etc. The CY-BOCS is measured from 0 to 40, with larger values indicating more severe symptoms. Our outcome measure was the difference between the post treatment and randomization scores. When those values are negative, it indicates a reduction in symptom severity. |
| Secondary | Clinical Global Impression-Severity (CGI-Severity) | Change from Randomization Point to Post Treatment | The Clinical Global Impression-Severity is a 7-point clinician rating of illness severity, with a score of 0 indicating no illness and a score of 6 indicating extremely severe symptoms. Because the secondary outcome was the change in score from randomization to post treatment, a more negative score indicates a greater reduction in symptom severity. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) | Change from Score at Randomization to Post Treatment | Change in score from randomization | MEAN | |
| SECONDARY | Clinical Global Impression-Severity (CGI-Severity) | Change from Randomization Point to Post Treatment | Change in score from randomization | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) | D-Cycloserine | -10.35 | Standard Deviation 7.72 | Change in score from randomization | |
| Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) | Sugar Pill | -9.40 | Standard Deviation 7.05 | Change in score from randomization | |
| Clinical Global Impression-Severity (CGI-Severity) | D-Cycloserine | -1.39 | Standard Deviation 1.04 | Change in score from randomization | |
| Clinical Global Impression-Severity (CGI-Severity) | Sugar Pill | -1.2 | Standard Deviation .91 | Change in score from randomization |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | D-Cycloserine | 70 | |
| Overall Study | STARTED | Sugar Pill | 72 | |
| Overall Study | COMPLETED | D-Cycloserine | 67 | |
| Overall Study | COMPLETED | Sugar Pill | 72 | |
| Overall Study | NOT COMPLETED | D-Cycloserine | 3 | |
| Overall Study | NOT COMPLETED | Sugar Pill | 0 |
Source ClinicalTrials.gov
Adverse events80
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Headache | Nervous system disorders | D-Cycloserine | 39 | 70 | |
| other | Headache | Nervous system disorders | Sugar Pill | 33 | 72 | |
| other | Constipation | Gastrointestinal disorders | D-Cycloserine | 17 | 70 | |
| other | Constipation | Gastrointestinal disorders | Sugar Pill | 9 | 72 | |
| other | Poor Memory | Nervous system disorders | D-Cycloserine | 19 | 70 | |
| other | Poor Memory | Nervous system disorders | Sugar Pill | 8 | 72 | |
| other | Nausea or Vomiting | Gastrointestinal disorders | D-Cycloserine | 23 | 70 | |
| other | Nausea or Vomiting | Gastrointestinal disorders | Sugar Pill | 25 | 72 | |
| other | Feeling Drowsy or Sleepy | General disorders | D-Cycloserine | 27 | 70 | |
| other | Feeling Drowsy or Sleepy | General disorders | Sugar Pill | 28 | 72 |
1 to 10 of 80Source ClinicalTrials.gov
See all 80 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | D-Cycloserine | ||
| Total, all-cause mortality | Sugar Pill | ||
| Total, other adverse events | D-Cycloserine | 60 | 70 |
| Total, other adverse events | Sugar Pill | 70 | 72 |
| Total, serious adverse events | D-Cycloserine | 0 | 70 |
| Total, serious adverse events | Sugar Pill | 0 | 72 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 20817153 | BACKGROUND |
Source PubMed
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01MH093402 | 2/2-D-Cycloserine Augmentation of CBT for Pediatric OCD | GELLER, DANIEL A | MASSACHUSETTS GENERAL HOSPITAL | NATIONAL INSTITUTE OF MENTAL HEALTH | 2011 to 2014 |
Source NIH RePORTER
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| D-Cycloserine vs Sugar Pill: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01404208
GET https://conductscience.org/api/trials/v1/NCT01404208/events?page=2